A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients
ABSTRACT Lyme disease is the most common vector-borne disease in the United States, with an estimated incidence of 300,000 infections annually. Antibiotic intervention cures Lyme disease in the majority of cases; however, 10 to 20% of patients develop posttreatment Lyme disease syndrome (PTLDS), a d...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6ce4b7f151484fb790e5b749f9d0ebd2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6ce4b7f151484fb790e5b749f9d0ebd2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6ce4b7f151484fb790e5b749f9d0ebd22021-11-15T16:19:08ZA Distinct Microbiome Signature in Posttreatment Lyme Disease Patients10.1128/mBio.02310-202150-7511https://doaj.org/article/6ce4b7f151484fb790e5b749f9d0ebd22020-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02310-20https://doaj.org/toc/2150-7511ABSTRACT Lyme disease is the most common vector-borne disease in the United States, with an estimated incidence of 300,000 infections annually. Antibiotic intervention cures Lyme disease in the majority of cases; however, 10 to 20% of patients develop posttreatment Lyme disease syndrome (PTLDS), a debilitating condition characterized by chronic fatigue, pain, and cognitive difficulties. The underlying mechanism responsible for PTLDS symptoms, as well as a reliable diagnostic tool, has remained elusive. We reasoned that the gut microbiome may play an important role in PTLDS given that the symptoms overlap considerably with conditions in which a dysbiotic microbiome has been observed, including mood, cognition, and autoimmune disorders. Analysis of sequencing data from a rigorously curated cohort of patients with PTLDS revealed a gut microbiome signature distinct from that of healthy control subjects, as well as from that of intensive care unit (ICU) patients. Notably, microbiome sequencing data alone were indicative of PTLDS, which presents a potential, novel diagnostic tool for PTLDS. IMPORTANCE Most patients with acute Lyme disease are cured with antibiotic intervention, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as posttreatment Lyme disease syndrome (PTLDS). The etiology of PTLDS is not understood, and objective diagnostic tools are lacking. PTLDS symptoms overlap several diseases in which patients exhibit alterations in their microbiome. We found that patients with PTLDS have a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. The signature is characterized by an increase in Blautia, a decrease in Bacteroides, and other changes. Importantly, this signature supports the validity of PTLDS and is the first potential biological diagnostic tool for the disease.Madeleine MorrissetteNorman PittAntonio GonzálezPhilip StrandwitzMariaelena CaboniAlison W. RebmanRob KnightAnthony D’OnofrioJohn N. AucottMark J. SoloskiKim LewisAmerican Society for MicrobiologyarticleLyme diseasediagnosticsmicrobial communitiesmicrofloratick-borne pathogensMicrobiologyQR1-502ENmBio, Vol 11, Iss 5 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Lyme disease diagnostics microbial communities microflora tick-borne pathogens Microbiology QR1-502 |
| spellingShingle |
Lyme disease diagnostics microbial communities microflora tick-borne pathogens Microbiology QR1-502 Madeleine Morrissette Norman Pitt Antonio González Philip Strandwitz Mariaelena Caboni Alison W. Rebman Rob Knight Anthony D’Onofrio John N. Aucott Mark J. Soloski Kim Lewis A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| description |
ABSTRACT Lyme disease is the most common vector-borne disease in the United States, with an estimated incidence of 300,000 infections annually. Antibiotic intervention cures Lyme disease in the majority of cases; however, 10 to 20% of patients develop posttreatment Lyme disease syndrome (PTLDS), a debilitating condition characterized by chronic fatigue, pain, and cognitive difficulties. The underlying mechanism responsible for PTLDS symptoms, as well as a reliable diagnostic tool, has remained elusive. We reasoned that the gut microbiome may play an important role in PTLDS given that the symptoms overlap considerably with conditions in which a dysbiotic microbiome has been observed, including mood, cognition, and autoimmune disorders. Analysis of sequencing data from a rigorously curated cohort of patients with PTLDS revealed a gut microbiome signature distinct from that of healthy control subjects, as well as from that of intensive care unit (ICU) patients. Notably, microbiome sequencing data alone were indicative of PTLDS, which presents a potential, novel diagnostic tool for PTLDS. IMPORTANCE Most patients with acute Lyme disease are cured with antibiotic intervention, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as posttreatment Lyme disease syndrome (PTLDS). The etiology of PTLDS is not understood, and objective diagnostic tools are lacking. PTLDS symptoms overlap several diseases in which patients exhibit alterations in their microbiome. We found that patients with PTLDS have a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. The signature is characterized by an increase in Blautia, a decrease in Bacteroides, and other changes. Importantly, this signature supports the validity of PTLDS and is the first potential biological diagnostic tool for the disease. |
| format |
article |
| author |
Madeleine Morrissette Norman Pitt Antonio González Philip Strandwitz Mariaelena Caboni Alison W. Rebman Rob Knight Anthony D’Onofrio John N. Aucott Mark J. Soloski Kim Lewis |
| author_facet |
Madeleine Morrissette Norman Pitt Antonio González Philip Strandwitz Mariaelena Caboni Alison W. Rebman Rob Knight Anthony D’Onofrio John N. Aucott Mark J. Soloski Kim Lewis |
| author_sort |
Madeleine Morrissette |
| title |
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| title_short |
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| title_full |
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| title_fullStr |
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| title_full_unstemmed |
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients |
| title_sort |
distinct microbiome signature in posttreatment lyme disease patients |
| publisher |
American Society for Microbiology |
| publishDate |
2020 |
| url |
https://doaj.org/article/6ce4b7f151484fb790e5b749f9d0ebd2 |
| work_keys_str_mv |
AT madeleinemorrissette adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT normanpitt adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT antoniogonzalez adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT philipstrandwitz adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT mariaelenacaboni adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT alisonwrebman adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT robknight adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT anthonydonofrio adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT johnnaucott adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT markjsoloski adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT kimlewis adistinctmicrobiomesignatureinposttreatmentlymediseasepatients AT madeleinemorrissette distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT normanpitt distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT antoniogonzalez distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT philipstrandwitz distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT mariaelenacaboni distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT alisonwrebman distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT robknight distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT anthonydonofrio distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT johnnaucott distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT markjsoloski distinctmicrobiomesignatureinposttreatmentlymediseasepatients AT kimlewis distinctmicrobiomesignatureinposttreatmentlymediseasepatients |
| _version_ |
1718426906119897088 |